LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

Exclusion Criteria

• •Patients with diffuse large B cell lymphoma previously treated.
• •Patients with primary central nervous system lymphoma.
• •Patients with Burkitt or Burkitt-like NHL.
• •CD4+ lymphocyte count \< 100/µL
• •Opportunistic infections or other AIDS-related neoplasias in activity.
• •Active drug-addiction.
• •Pregnant or lactating women or adults of fertile age who do not use an effective contraceptive method.
• •Patients with serious altered renal function (creatinine \> 2.5 x upper limit of normal \[ULN\]) or hepatic \[bilirubin, ALT or AST \> 2.5 x ULN\], except if the investigators suspect that they are caused by the disease.
• •Cardiac insufficiency with ejection fraction \< 40%
• •Patients with serious psychiatric diseases that can interfere with their capacity to understand the study (including alcoholism or active drug-addiction).
• •ECOG \> 3
• •Patients with a known hypersensitivity to murine proteins or any other component of the study drugs.